Clinical trialNCT06293898RecruitingPhase 1Interventional

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

SponsorSystImmune Inc.Enrollment280Biliary Tract CancerBreast CancerCervical CancerEndometrial CancerEsophageal CancerGastric Cancer+4 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Clinical Leader
SystImmune Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

17 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Alabama Birmingham
Birmingham, Alabama, United States
Nusrat Jahan, MD
Recruiting
City of Hope
Duarte, California, United States
Abhishek Tripathi, MD
Recruiting
Cedars Sinai
Los Angeles, California, United States
Jin Sun Bitar, MD
Recruiting
Scripps Health
San Diego, California, United States
Wesleigh Edwards, MD
Not, yet, recruiting
University of Miami
Miami, Florida, United States
Gilberto Lopes, MD
Recruiting
Sarah Cannon Research Institute - Lake Nona Florida
Orlando, Florida, United States
Cesar Perez Batista, MD
Recruiting
Georgia Cancer Center at Augusta University
Augusta, Georgia, United States
Sharad Ghamande, MD
Recruiting
University of Chicago Medicine
Chicago, Illinois, United States
Gini Fleming, MD
Recruiting
University of Illinois Cancer Center
Chicago, Illinois, United States
Oana Danciu, MD
Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Joyce Liu, MD
Recruiting
Karmanos Cancer Institiute
Detroit, Michigan, United States
Wasif Saif, MD
Recruiting
Nyu Langone Hospital - Long Island Investigational Pharmacy
Mineola, New York, United States
Nancy Chan, MD
Recruiting
Laura & Isaac Perlmutter Cancer Center at Nyu Langone Health
New York, New York, United States
Nancy Chan, MD
Recruiting
Providence Portland Medical Center
Portland, Oregon, United States
Rachel Sanborn, MD
Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee, United States
Erica Hamilton, MD
Recruiting
Oncology Consultants
Houston, Texas, United States
Julio Peguero, MD
Recruiting
Virginia Cancer Specialists
Fairfax, Virginia, United States
Alexander Spira, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

BL-M07D1

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 9 Feb 2024
Primary completion: 15 Dec 2028
Completion: 15 Apr 2029
Last update posted: 20 Jul 2026
Registered enrollment: 280
Registry id: NCT06293898

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.